Detection of Antibodies Directed Towards Dengue Virus by PRNT<<Return to Laboratory
Serological detection of neutralizing antibodies directed towards dengue (DEN) virus by Plaque Reduction Neutralization Test (PRNT).
- Dengue hemorrhagic fever (DHF)
- Dengue fever
- Dengue shock syndrome
Serum. Minimum volume of 250 µl required.
2 mL screw cap tubes.
Store samples refrigerated or frozen until shipped for testing. Ship frozen samples on dry ice, and refrigerated samples on wet ice
Shipping of specimens shall be done by a TDG certified individual in accordance with TDG regulations. For additional information regarding classification of specimens for the purposes of shipping, consult either Part 2 Appendix 3 of the TDG Regulations or section 3.6.2 of the IATA Dangerous Goods Regulations as applicable.
For additional guidance on the transport of infectious substances in other languages, please click on the link below.
Suspected dengue virus infection and relevant travel history. Submitted samples will first be analysed by the Viral Zoonoses Diagnostic Laboratory by Dengue IgM/IgG ELISA to determine if the patient has developed anti-flavivirus antibodies. Samples that are reactive can be further analysed for the presence of neutralizing antibodies. Samples that are ELISA non reactive (negative) will not be tested by PRNT.
Completed Viral Zoonoses requisition including sender laboratory name, address and telephone number. Patient name and / or identifier (specimen reference number), date of birth, test(s) requested, collection date of specimen, date of on-set of symptoms, and clinical and travel history of patient.
Dengue PRNT is often performed alongside other flavivirus PRNT to differentiate virus causing illness due to the high level of seroprevalence of Dengue virus.
Antibodies directed towards dengue virus can cross react significantly in some serological assays (Zika, West Nile Virus, etc.). The PRNT is a more specific assay and can be used to document the presence of serum antibodies specific for a particular flavivirus. Serum samples are incubated with virus and if viral neutralizing antibodies are present, they will bind to the dengue virus and prevent viral infection of cultural cells, and hence a reduction in the number of plaques detected. The neutralizing titre of a sample is expressed as the reciprocal of the serum dilution at which there is a 90% reduction in the number of plaques detected. If the patient has experienced more than one flavivirus infection, cross reactive results may yield uninterpretable results with this assay despite increased specificity.
Due to the cross-reactive nature of anti-flavivirus antibody, the detection of anti-flavivirus IgG (i.e.. Zika, JE etc.) in a single serum sample is indicative of past or present exposure to this agent, or a related agent from the same virus genus. The presence of anti-dengue virus specific IgM in a single serum sample is consistent with an acute infection with this virus and meets the criteria for a "probable case". However, a 4-fold rise or greater in neutralizing antibody titre, or an IgG or IgM seroconversion in paired sera, is required to document a "confirmed case" of infection with associated illness.
There is increasing evidence for IgM persistence in blood/serum for up to a year or more after arbovirus (Eg. members of the Flavivirus, alphavirus, and bunyavirus arthropod borne virus groups) exposure. Thus, detection of IgM by itself may not always be a confirmation of acute infection.
Isolation of an arbovirus, detection of specific antibody by plaque reduction neutralization assay or detection of nucleic acid by Real Time RT-PCR in a clinical specimen would constitute firm evidence of viral association with illness and provide "confirmed case" status.
21 calendar days after the completion of preliminary ELISA testing.
- WHO. 2007. Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses.